ADHD stimulant shortages worsen suicide risks for youth with substance use disorder

New research highlights the critical role of stimulant therapy in reducing suicidal thoughts and attempts among individuals with both ADHD and substance use disorder (SUD). Despite proven benefits, medication shortages and clinician hesitation have worsened health outcomes for this vulnerable group. Over the past five years, these challenges have led to a noticeable rise in hospitalisations among young people with the dual diagnosis.

ADHD affects around 12–13% of US adolescents, often disrupting daily life and increasing the risk of developing SUD. When both conditions co-occur, effective treatment becomes even more urgent. Studies, including one from Penn State College of Medicine, reveal a concerning treatment gap: youth aged 15 to 25 with ADHD and SUD frequently miss out on necessary stimulant medications.

Between 2021 and 2025, persistent shortages of ADHD medications—driven by surging post-COVID demand and production delays—have worsened the situation. The CDC and JAMA report a 12–18% increase in hospitalisations among adolescents and young adults with comorbid ADHD and SUD. Poor symptom control, higher relapse rates, and acute behavioural crises have become more common during these shortages. Clinicians often hesitate to prescribe stimulants due to fears of misuse and strict regulations. Data shows that the likelihood of starting or continuing stimulant therapy drops significantly after an SUD diagnosis. This reluctance persists despite evidence that ADHD pharmacotherapy, including stimulants, improves health outcomes and lowers mortality risk in these patients. Experts now call for updates to health policies and clinical training. They emphasise the need to balance misuse concerns with the proven benefits of stimulant treatment. Further research is also needed to explore the barriers—clinical, social, and demographic—that limit access to effective ADHD care.

The findings underscore the importance of stimulant therapy in managing ADHD and SUD together. Without better access to these medications, hospitalisation rates and relapse risks will likely remain high. Policymakers and healthcare providers are urged to align practices with current evidence to improve outcomes for this at-risk population.